AAREYDRUGS vs VENUSREM: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Venus Remedies Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Venus Remedies Limited is the larger company by market capitalisation. Venus Remedies Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Venus Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 1 of 13 scored metrics and VENUSREM on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
VENUSREM is the larger company
₹2,270 Cr vs ₹221 Cr
P/E Ratio
VENUSREM has a lower P/E
20.57x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 3.6x
EPS
VENUSREM has higher earnings per share
₹76.93 vs ₹1.47
Dividend Yield
VENUSREM has a higher dividend yield
0.56% vs 0%
Revenue Growth (TTM YoY)
VENUSREM has faster revenue growth
33% vs 19.8%
EPS Growth (TTM YoY)
VENUSREM has faster EPS growth
126.4% vs -41.05%
Qtr Sales Growth
VENUSREM has stronger quarterly sales growth
21.4% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSVENUSREM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSVENUSREM
Live Price₹90.51₹1,797.5
Day Change-4.92%4.8%
Volume2.2 L2.46 L
52-Week High₹96₹1,800.8
52-Week Low₹50.31₹424
Distance from 52W High-5.72%-0.18%

Valuation

MetricAAREYDRUGSVENUSREM
Market Cap₹221 Cr₹2,270 Cr
P/E Ratio55.36x20.57x
P/B Ratio1.46x3.6x
EPS₹1.47₹76.93
Book Value₹48.67₹444.63
Dividend Yield0%0.56%

Growth

MetricAAREYDRUGSVENUSREM
Revenue Growth (TTM YoY)19.8%33%
EPS Growth (TTM YoY)-41.05%126.4%
Qtr Sales Growth0%21.4%
Qtr Profit Growth0%687%

Profitability & Leverage

MetricAAREYDRUGSVENUSREM
ROE2.64%15.48%
ROCE6%11.1%
Net Margin0.84%13.35%
Operating Margin2.21%17.44%
Debt to Equity0.33x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSVENUSREM
Promoter Holding37.71% 1.35 pp41.76%
FII Holding4.18% 0.32 pp2.92% 0.12 pp
DII Holding1.62% 1.62 pp0.89% 0.31 pp
Public Holding56.49% 0.6 pp54.43% 0.19 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Venus Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.